Zydus Cadila

Ahmedabad, India Founded: 1952 • Age: 74 yrs Listed
Pharmaceutical manufacturing, drug development, and healthcare services.
Request Access
Report Incorrect Data
Page last updated

About Zydus Cadila

Zydus Cadila is a publicly listed company based in Ahmedabad (India) founded in 1952. Pharmaceutical manufacturing, drug development, and healthcare services. The company has 24,487 employees. Zydus Cadila has completed 3 acquisitions, including Etna Biotech, Sentynl Therapeutics and The Kraft Heinz Company. Its website zyduscadila.com draws about 26 thousand monthly visits. Its Indian entity Zydus Lifesciences Limited reported revenue of ₹51,690 Cr. Zydus Cadila offers products and services including Pharmaceutical Drugs and Biotech Services. Its focus areas include Pharmaceuticals, Drug Manufacturing, Generic Medications and Biotechnology.

Company details

Zydus Life is recognized as a company that operates in the pharmaceutical and biotechnology sectors, where products are developed and distributed globally to meet healthcare demands. Investments in research are made to ensure compliance with industry standards, and operations are conducted with a focus on quality and accessibility. Partnerships with various entities are utilized to enhance product availability, while contributions to medical advancements are noted through ongoing innovations. The companys activities are managed under regulatory frameworks to maintain reliability in the market.

  • Headquarters Ahmedabad, India
  • Employees 24,487
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website zyduscadila.com
  • Social LinkedIn X Facebook
  • Legal Name Zydus Lifesciences Limited
  • Date of Incorporation 15 May, 1995
  • Jurisdiction Ahmedabad, Gujarat, India
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Healthcare → Immunology & Cancer Therapeutics
Key Metrics
  • Market Cap
    ₹1,19,002 Cr

    ZYDUSLIFE · NSE

  • Share Price
    ₹1,197.90

    +0.41% today

  • Revenue
    ₹51,180 Cr

    FY 2025-26 · +13.2% YoY

  • EBITDA
    ₹7,958 Cr

    Margin 15.6%

  • Net Profit
    ₹5,432 Cr

    FY 2025-26 · +16.8% YoY

  • P/E (TTM)
    26.1x

    P/B 4.3x

  • ROE
    19.7%

    ROCE 20.3%

  • Debt / Equity
    0.31

    Interest cover 6.7x

  • Employee Count
    24,487
  • Investments & Acquisitions
    Etna Biotech

    & 2 more

Products & Services of Zydus Cadila

Zydus Cadila offers a comprehensive portfolio of products and services, including Pharmaceutical Drugs and Biotech Services.

Pharmaceutical Drugs
Healthcare Products

Drugs are manufactured and supplied for various medical applications

Biotech Services
Research Services

Biotechnology research and development services are provided to support industry needs

Board of directors of Zydus Lifesciences Limited (Zydus Cadila)

Zydus Lifesciences Limited is the primary company behind Zydus Cadila. The board of Zydus Lifesciences Limited currently have 9 directors; the longest-serving is Pankaj Ramanbhai Patel, appointed in 1995. 10 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Pankaj Ramanbhai Patel
DIN 00131852
Director15 May 199531 yrs 5 moZydus Lifesciences Limited
Sharvil Pankajbhai Patel
DIN 00131995
Managing Director01 Aug 199729 yrs 3 moZydus Lifesciences Limited
Mukesh Mangalbhai Patel
DIN 00053892
Director01 Aug 199729 yrs 3 moZydus Lifesciences Limited
Ganesh Narayan Nayak
DIN 00017481
Director12 Jul 20179 yrs 3 moZydus Lifesciences Limited
Bhadresh Kantilal Shah
DIN 00058177
Director06 Dec 20187 yrs 11 moZydus Lifesciences Limited
Monappa Arun Akhil
DIN 09784366
Director29 Nov 20223 yrs 11 moZydus Lifesciences Limited
Upasana Konidela
DIN 02781278
Director29 Nov 20223 yrs 11 moZydus Lifesciences Limited
Shelina Pranav Parikh
DIN 00468199
Director17 May 20242 yrs 5 moZydus Lifesciences Limited
Kulin Sanjay Lalbhai
DIN 05206878
Director19 May 20265 moZydus Lifesciences Limited

People of Zydus Cadila

52 people are tracked at Zydus Cadila (21 in leadership, 9 in board & advisors, 22 in team); the tracked headcount is 24,487.

NameRoleGroup
Devi Prasad
Deputy General ManagerLeadership
Shekhar Gupta
Marketing HeadLeadership
Parul Sood
General Manager Sales & MarketingLeadership
Nirmal Kumar
Senior General Manager & Head Of Chemistry, Manufacturing And ControlsLeadership
Dr. Ravi Mehta
Deputy General ManagerLeadership
Darpan Shah
General ManagerLeadership
Rajesh Maheshwari
Deputy General ManagerLeadership
Punit Patel
President and Chief Executive Officer, AmericasLeadership
Rajesh Naik
Sr Vice President Operation :overall Manufacturing HeadLeadership
Sapan Parikh
Vice President & Head - Project ManagementLeadership
Sandip Darji
Senior General ManagerLeadership
Vishal Shah
Deputy General ManagerLeadership
Manoj Gera
Deputy General ManagerLeadership
Abhimanyu Singh
Sr. General Manager- Sales And MarketingLeadership
Ravi Bordia
Deputy General ManagerLeadership
Rahul Pradhan
Vice President Of ManufacturingLeadership
Devendra Tripathi
Deputy General ManagerLeadership
Nitin Mathur
Senior General Manager - Planning & LogisticsLeadership
Suman Kumar
Vice PresidentLeadership
Ashish Kumar
Sr Vice PresidentLeadership

32 more people are available in the full profile.

Premium access

Complete people profiles for Zydus Cadila

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Zydus Cadila

Zydus Cadila is a publicly listed company on the NSE with ticker symbol ZYDUSLIFE in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: ZYDUSLIFE
  • Listed entityZydus Lifesciences Limited
  • Exchange sectorPharmaceuticals

Financials of Zydus Cadila

Exchange-reported figures of Zydus Lifesciences Limited, the listed company behind Zydus Cadila (NSE: ZYDUSLIFE).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹51,180 Cr
+13.2% YoY
EBITDA
₹7,958 Cr
+16.4% YoY
Profit After Tax
₹5,432 Cr
+16.8% YoY
Net Worth
₹27,111 Cr
+13.2% YoY
Total Assets
₹43,600 Cr
+41.4% YoY
Total Debt
₹12,496 Cr
+288.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue51,18045,20219,54717,23715,26515,10214,253
Revenue growth+13.2%+131.2%+13.4%+12.9%+1.1%+6.0%-
EBITDA7,9586,8395,3673,2513,3413,1362,420
EBITDA margin+15.6%+15.1%+27.5%+18.9%+21.9%+20.8%+17.0%
Profit before tax6,6216,0274,8322,5855,0842,2851,495
Net profit5,4324,6503,8602,3884,3652,3001,437
Net profit margin+10.6%+10.3%+19.8%+13.9%+28.6%+15.2%+10.1%
EPS (₹)50.1044.9938.3619.3743.8220.8411.49
Balance sheet
Total assets43,60030,82924,27421,21023,65819,88719,979
Net worth27,11123,95319,83017,51617,00012,99210,376
Total debt12,4963,2138041,1954,2214,6087,986
Cash & bank1,4172,9571,1055731,107888965
Net working capital7,0586,3306,6075,0375,7584,6395,005
Cash flow
Cash from operations2,1176,7813,1962,6892,1043,2942,932
Cash from investing(7,895)(8,363)(1,492)1,542(1,018)(837)(1,004)
Cash from financing5,8071,995(1,779)(4,400)(868)(2,548)(1,528)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue7,9108,0177,5876,8646,1236,5746,5285,269
Revenue growth (YoY)+29.2%+22.0%+16.2%+30.3%+16.9%+5.9%--
Other income15914413411110915580.6057.50
EBITDA1,8941,9112,1571,7321,9822,0881,9061,387
EBITDA margin+24.4%+24.5%+29.0%+25.5%+32.8%+32.3%+30.3%+27.1%
Depreciation604530508360302238238229
Interest18715612313010184.7076.6032.00
Profit before tax1,2621,3691,6601,3531,6871,9211,6721,184
Tax334358318388454434423180
Net profit9281,0111,3419651,2331,4871,2491,004
EPS (₹)9.289.5612.6510.3612.5114.5811.6410.17
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue11,48615,11810,8188,7337,8357,7806,347
Revenue growth-24.0%+39.8%+23.9%+11.5%+0.7%+22.6%-
EBITDA3,7587,7364,0502,2511,5992,1211,371
EBITDA margin+32.7%+51.2%+37.4%+25.8%+20.4%+27.3%+21.6%
Profit before tax4,3827,4454,2402,0321,1641,6881,617
Net profit3,6915,7323,4351,6211,0961,6331,466
Net profit margin+32.1%+37.9%+31.8%+18.6%+14.0%+21.0%+23.1%
EPS (₹)35.3957.4034.2115.118.3814.4213.80
Balance sheet
Total assets31,40629,79822,10418,63116,09616,84415,088
Net worth23,67221,19015,71613,63913,24012,74411,260
Total debt7,4428,3426,1784,8252,6653,9203,695
Cash & bank734144414248303154385
Net working capital9,6538,7055,9895,2185,1264,5193,527
Cash flow
Cash from operations2,2343,1142,0001,0781,2722,2271,181
Cash from investing570(4,504)(1,832)(1,959)586(2,714)54.60
Cash from financing(2,580)1,384(301)827(1,710)255(967)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3,4822,8723,7412,2842,8712,5885,8202,516
Revenue growth (YoY)+21.3%+11.0%-35.7%-9.2%+9.6%-37.8%--
Other income16512449547454215718577.50
Total expenses2,4282,2851,8592,1451,7192,0032,0471,867
EBITDA1,0545871,8821391,1525853,773648
EBITDA margin+31.4%+21.6%+52.8%+6.3%+41.0%+23.5%+67.0%+26.9%
Depreciation155152151144136130128132
Interest10110311611611413815597.20
Profit before tax9624562,1113521,4444753,675497
Tax24811638955.9028790.2086126.60

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue7,9108,0177,5876,8646,1236,5746,5285,269
Revenue growth (YoY)+29.2%+22.0%+16.2%+30.3%+16.9%+5.9%--
Other income15914413411110915580.6057.50
EBITDA1,8941,9112,1571,7321,9822,0881,9061,387
EBITDA margin+24.4%+24.5%+29.0%+25.5%+32.8%+32.3%+30.3%+27.1%
Depreciation604530508360302238238229
Interest18715612313010184.7076.6032.00
Profit before tax1,2621,3691,6601,3531,6871,9211,6721,184
Tax334358318388454434423180
Net profit9281,0111,3419651,2331,4871,2491,004
EPS (₹)9.289.5612.6510.3612.5114.5811.6410.17
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue51,18045,20219,54717,23715,26515,10214,253
Revenue growth+13.2%+131.2%+13.4%+12.9%+1.1%+6.0%-
Other income5102703111872,58337.20114
Total expenses43,22238,36314,18113,98611,92411,96611,833
Employee cost4,4183,6813,1382,7662,4342,4902,414
EBITDA7,9586,8395,3673,2513,3413,1362,420
EBITDA margin+15.6%+15.1%+27.5%+18.9%+21.9%+20.8%+17.0%
Depreciation1,408916764723713725696
Interest43916681.20130127164342
Profit before tax6,6216,0274,8322,5855,0842,2851,495
Tax1,5951,412978588512147320
Net profit5,4324,6503,8602,3884,3652,3001,437
Net profit margin+10.6%+10.3%+19.8%+13.9%+28.6%+15.2%+10.1%
EPS (₹)50.1044.9938.3619.3743.8220.8411.49
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital101101101101102102102
Reserves & surplus27,01123,85219,72917,41516,89712,89010,273
Shareholders' funds (net worth)27,11123,95319,83017,51617,00012,99210,376
Minority interest2,4712,4052,2722,1722,0541,9371,335
Secured loans2,2072,1500.000.005003841,873
Unsecured loans10,2891,0648041,1953,7214,2246,113
Total debt12,4963,2138041,1954,2214,6087,986
Total liabilities43,60030,82924,27421,21023,65819,88719,979
Assets
Gross block34,31021,70019,92018,34417,65117,34516,782
Net block24,10613,13412,36811,52112,18812,13312,230
Capital work in progress3,6982,6922,4231,201726783742
Investments7,5406,4121,2201,5473,288830765
Inventories5,6283,9443,4423,4133,7193,2362,789
Sundry debtors5,4164,0855,2204,4173,3403,1273,663
Cash & bank balances1,4172,9571,1055731,107888965
Loans & advances1,6701,2051,4009861,5751,2651,086
Total current assets14,13012,19111,1679,3899,7428,5178,503
Total current liabilities7,0725,8604,5614,3523,9843,8783,498
Net working capital7,0586,3306,6075,0375,7584,6395,005
Total assets43,60030,82924,27421,21023,65819,88719,979
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash8274134886588881,178779
Net cash from operating activities2,1176,7813,1962,6892,1043,2942,932
Net cash from investing activities(7,895)(8,363)(1,492)1,542(1,018)(837)(1,004)
Net cash from financing activities5,8071,995(1,779)(4,400)(868)(2,548)(1,528)
Net change in cash28.40414(74.80)(170)219(90.50)399
Closing cash1,4172,9571,1055731,107888965
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.2%+131.2%+13.4%+12.9%+1.1%+6.0%-
EBITDA growth+16.4%+27.4%+65.1%-2.7%+6.5%+29.6%-
PBT growth+9.9%+24.7%+86.9%-49.2%+118.1%+55.9%-37.2%
Net income growth+16.8%+20.5%+61.7%-45.3%+89.8%+60.0%-
Revenue CAGR (3Y)+15.0%+15.8%+10.0%+3.9%+30.3%+33.5%+47.4%
EBITDA CAGR (3Y)+34.8%+27.0%+19.9%+10.3%+4.0%+3.3%+8.4%
Profitability & leverage
Net income margin+9.8%+10.2%+10.2%+5.9%+15.7%+7.5%+3.9%
Return on capital employed+20.3%+24.6%+23.9%+16.3%+14.4%+15.1%+11.9%
Return on net worth+19.7%+21.1%+20.6%+14.1%+29.7%+19.7%+14.2%
Debt / equity0.310.090.050.160.290.540.77
Long-term debt / equity0.080.000.000.010.030.160.35
Interest cover6.702.801.765.144.836.5019.83
Efficiency & per share
Fixed asset turnover1.832.171.971.871.661.661.85
Inventory turnover10.6912.2411.009.458.379.4110.97
Debtors turnover10.779.727.838.699.008.357.89
EPS (₹)50.1044.9938.3619.3743.8220.8411.49
Dividend per share (₹)1.0011.003.006.002.503.503.50
Book value per share (₹)269.50238.10197.11173.08166.01126.88101.33
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3,4822,8723,7412,2842,8712,5885,8202,516
Revenue growth (YoY)+21.3%+11.0%-35.7%-9.2%+9.6%-37.8%--
Other income16512449547454215718577.50
Total expenses2,4282,2851,8592,1451,7192,0032,0471,867
EBITDA1,0545871,8821391,1525853,773648
EBITDA margin+31.4%+21.6%+52.8%+6.3%+41.0%+23.5%+67.0%+26.9%
Depreciation155152151144136130128132
Interest10110311611611413815597.20
Profit before tax9624562,1113521,4444753,675497
Tax24811638955.9028790.2086126.60
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue11,48615,11810,8188,7337,8357,7806,347
Revenue growth-24.0%+39.8%+23.9%+11.5%+0.7%+22.6%-
Other income1,6686961,08554817989.30909
Total expenses7,7287,3826,7686,4826,2365,6594,976
Employee cost1,9661,7621,5081,3221,2051,1471,077
EBITDA3,7587,7364,0502,2511,5992,1211,371
EBITDA margin+32.7%+51.2%+37.4%+25.8%+20.4%+27.3%+21.6%
Depreciation561524504489479451429
Interest48346439127813570.90234
Profit before tax4,3827,4454,2402,0321,1641,6881,617
Tax8221,670798503306212204
Net profit3,6915,7323,4351,6211,0961,6331,466
Net profit margin+32.1%+37.9%+31.8%+18.6%+14.0%+21.0%+23.1%
EPS (₹)35.3957.4034.2115.118.3814.4213.80
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital101101101101102102102
Reserves & surplus23,57121,09015,61613,53813,13812,64211,158
Shareholders' funds (net worth)23,67221,19015,71613,63913,24012,74411,260
Secured loans2,1992,1500.000.00500994357
Unsecured loans5,2436,1936,1784,8252,1652,9263,338
Total debt7,4428,3426,1784,8252,6653,9203,695
Total liabilities31,40629,79822,10418,63116,09616,84415,088
Assets
Gross block10,2948,9008,6778,0007,6767,0096,564
Net block5,0844,2024,3694,1844,3364,1124,109
Capital work in progress6211,188634739384570553
Investments11,47811,4927,2834,8795,1186,4716,404
Inventories2,1781,9521,6871,7821,9261,7801,395
Sundry debtors8,4958,1624,7403,5052,2781,9042,457
Cash & bank balances734144414248303154385
Loans & advances6408201,0701,4212,1102,194556
Total current assets12,04711,0787,9116,9576,6176,0324,793
Total current liabilities2,3942,3731,9221,7381,4901,5131,266
Net working capital9,6538,7055,9895,2185,1264,5193,527
Total assets31,40629,79822,10418,63116,09616,84415,088
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash103108240294154385117
Net cash from operating activities2,2343,1142,0001,0781,2722,2271,181
Net cash from investing activities570(4,504)(1,832)(1,959)586(2,714)54.60
Net cash from financing activities(2,580)1,384(301)827(1,710)255(967)
Net change in cash224(5.10)(132)(54.10)149(231)268
Closing cash734144414248303154385
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-24.0%+39.8%+23.9%+11.5%+0.7%+22.6%-
EBITDA growth-51.4%+91.0%+80.0%+40.8%-24.6%+54.7%-
PBT growth-41.1%+75.6%+108.6%+74.6%-31.1%+4.4%-9.5%
Net income growth-35.6%+66.9%+111.9%+48.0%-32.9%+11.4%-
Revenue CAGR (3Y)+9.6%+24.5%+11.6%+11.2%+9.1%+10.2%+25.3%
EBITDA CAGR (3Y)+18.6%+69.1%+24.1%+18.0%-0.6%+8.8%+62.2%
Profitability & leverage
Net income margin+31.0%+38.2%+31.8%+17.5%+11.0%+19.0%+22.3%
Return on capital employed+15.9%+30.5%+22.7%+13.3%+9.8%+12.2%+13.5%
Return on net worth+15.9%+31.3%+23.5%+11.4%+8.4%+13.6%+14.3%
Debt / equity0.350.390.370.280.250.320.37
Long-term debt / equity0.160.230.320.150.030.090.18
Interest cover15.106.4311.0215.7912.044.2524.82
Efficiency & per share
Fixed asset turnover1.201.721.301.111.071.151.00
Inventory turnover5.568.316.244.714.234.904.43
Debtors turnover1.382.342.623.023.753.572.78
EPS (₹)35.3957.4034.2115.118.3814.4213.80
Dividend per share (₹)1.0011.003.006.002.503.503.50
Book value per share (₹)235.31210.64156.23134.78129.30124.46109.96

Investments & Acquisitions by Zydus Cadila

Zydus Cadila has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Etna Biotech, Sentynl Therapeutics and The Kraft Heinz Company.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
The Kraft Heinz Company
Surplus products are branded and distributed across India.
heinz.co.inMumbai, India1994Oct 2018$628.05M
Sentynl Therapeutics
Novel biopharmaceutical medicines for rare diseases are developed.
sentynl.comSan Diego, United States2011Jan 2017••••
Etna Biotech
Vaccines and immunotherapeutics for infectious and chronic diseases are developed.
etnabiotech.itCatania, Italy2001Nov 2008••••
Premium access

Complete acquisition details for Zydus Cadila

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Zydus Cadila

4 dated milestones of Zydus Cadila across 66 years, from founding to its latest funding, stage changes and deals.

  1. Founded Zydus Cadila is founded.
  2. Acquisition Acquires Etna Biotech.
  3. Acquisition Acquires Sentynl Therapeutics.
  4. Acquisition Acquires The Kraft Heinz Company.

Web traffic of Zydus Cadila

The website of Zydus Cadila (zyduscadila.com) receives about 25.8K visits a month and ranks #1,058,292 among all websites worldwide, #1,307 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    25.8K

    ▲ 30.7% vs previous month

  • Unique visitors
    5.6K

    per month

  • Global rank
    #1,058,292

    among all websites

  • Category rank
    #1,307

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Zydus Cadila. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Cadila Pharmaceuticals Limited
cadilapharma.com
100%
18.5K#1,452,788View details
Zydus Life
zyduslife.com
86%
48.1K#726,817View details
Zydus Pharmaceuticals
zydususa.com
81%
#2,137,903View details
Lambda Therapeutic
lambda-cro.com
70%
38.8K#490,207View details
mintzassoc.com
mintzassoc.com
65%
–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 13 similar websites and full traffic analytics for Zydus Cadila

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 13 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Zydus Cadila

Zydus Life: Company Keeps FY27 Guidance for EBITDA Margin Over 24%, Expects Single-Digit Growth in Constant Currency for US Business, Including Mirabegron Competition - Concall Update.
Exchange Update • 2 days ago
Zydus Life: Expects Consistent Growth Of 200 To 400 Basis Points Above Indian Pharmaceutical Market Growth Of 10% To 11%
Exchange Update • 2 days ago
Zydus Lifesciences: Bernstein on Zydus Lifesciences maintains Buy, Target Price Rs 1457; Q2 revenue grew 29% YoY to Rs 79.1bn, ahead of estimates, although higher-than-expected spending ahead of the Saroglitazar launch weighed on margins. EBITDA margin was 24% against an estimated 25.5% excluding these investments. Bernstein reiterated its positive view on the innovation pipeline and expects an earnings inflection in FY28.
Exchange Update • 2 days ago
Zydus Lifesciences: CLSA on Zydus Lifesciences maintains Outperform, Target Price Rs 1390; Q2 revenue grew 29% YoY, driven by healthy performance across segments, while margins remained in line with guidance despite continued investment in the Saroglitazar launch. Management retained its FY27 guidance of single-digit US revenue growth, driven by new launches, and expects India to continue outperforming IPM growth. The company expects margins of 24% or higher.
Exchange Update • 2 days ago
ZYDUSLIFE: Q2 CONS NET PROFIT 9.3B RUPEES VS 12.6B (YOY); EST 9B
Exchange Update • 3 days ago
ZYDUSLIFE: Q2 REVENUE 79B RUPEES VS 61B (YOY)
Exchange Update • 3 days ago
ZYDUSLIFE: Q2 EBITDA 18.94B RUPEES VS 20.15B (YOY); Q2 EBITDA MARGIN 23.95% VS 32.92% (YOY)
Exchange Update • 3 days ago
Zydus Life: Reports Drop Of ₹700 Crore In Net Debt This Quarter
Exchange Update • 3 days ago
Zydus Lifesciences: Completes Purchase Of API Business From Sterling Biotech; Closing Follows Conditions Set In Transfer Agreement Dated September 17, 2024.
Exchange Update • 5 days ago
US FDA Flags Issues In Co's Data Integrity; US FDA Had Issued 5 Observations At Moraiya Unit ( Zydus Life ) - TV
Exchange Update • 12 days ago
Premium access

Complete news archive for Zydus Cadila

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Zydus Cadila

Zydus Cadila was founded in 1952.

Zydus Cadila is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

Zydus Cadila has 24,487 employees.

The primary company behind Zydus Cadila, Zydus Lifesciences Limited, reported revenue of ₹51,690 Cr for FY 2026, up 13% year on year.

Zydus Life is recognized as a company that operates in the pharmaceutical and biotechnology sectors, where products are developed and distributed globally to meet healthcare demands. Investments in research are made to ensure compliance with industry standards, and operations are conducted with a focus on quality and accessibility. Partnerships with various entities are utilized to enhance product availability, while contributions to medical advancements are noted through ongoing innovations. The companys activities are managed under regulatory frameworks to maintain reliability in the market.

Zydus Cadila offers Pharmaceutical Drugs and Biotech Services.

Yes, Zydus Cadila is publicly traded on NSE under the ticker symbol ZYDUSLIFE.

Zydus Cadila has made 3 acquisitions, including Etna Biotech, Sentynl Therapeutics, and The Kraft Heinz Company.

Zydus Cadila operates through Zydus Lifesciences Limited.

The legal entities of Zydus Cadila currently have 11 directors, including Sharvil Pankajbhai Patel, Bhadresh Kantilal Shah, Dhaval Narendra Soni and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available